1 / 23

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

<br /><br />E1308:<br />A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx. Presented By Anthony Cmelak at 2014 ASCO Annual Meeting. Disclosures.

tanner-farley
Download Presentation

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. <br /><br />E1308:<br />A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  3. Slide 3 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  4. Background: HPV+ OP SCCa Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  5. Rationale: Cetuximab based Induction CT Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  6. Slide 6 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  7. Endpoints Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  8. Statistics Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  9. Results Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  10. Slide 10 Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  11. Results: Acute Toxicity Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  12. Late Toxicity Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  13. Response: Induction Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  14. Response: Following Cetux/IMRT Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  15. Endpoint: 2yr PFS and OS Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  16. PFS and Survival: Dose Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  17. Low Dose: T stage and N stage Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  18. Smoking: PFS and Survival Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  19. Best Outcome: <T4, T1-N2b, <10 pk-yr Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  20. First Failure Patterns: Low-dose pts Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  21. Summary Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  22. Conclusions Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

  23. Designed and conducted by: Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

More Related